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Despite their initial characterization as histone deacetylases controlling transcription, 
sirtuins also turn out to be critical regulators of metabolism. In this issue of Cell, Haigis et 
al. (2006) demonstrate that the mammalian Sir2 homolog SIRT4 acts in the mitochondria 
of pancreatic β cells to repress the activity of glutamate dehydrogenase through ADP-
ribosylation. In this way, SIRT4 downregulates insulin secretion by β cells in response to 
amino acids.Mammalian cells contain seven 
homologs of the yeast Sir2 protein, 
SIRT1 to SIRT7 (reviewed in Blander 
and Guarente, 2004). The found-
ing member of the sirtuins, Sir2, is 
essential in yeast for maintaining 
chromatin in a silent state through 
the deacetylation of histones. 
Together, the sirtuins comprise the 
class III NAD+-dependent histone 
deacetylases (HDACs) that catalyze 
NAD+-dependent histone deacety-
lation, also producing nicotinamide 
and 2′-O-acetyl-ADP-ribose. How-
ever, as each sirtuin has been char-
acterized, an increasing number of 
exceptions to this classification have 
been found, including nonhistone 
sirtuin substrates, the localization 
of sirtuins outside the nucleus, and 
the absence of deacetylase activity. 
The report by Haigis et al. (2006) in 
this issue of Cell that SIRT4 is a mito-
chondrial sirtuin regulating gluta-
mate dehydrogenase (GDH) activity 
through ADP-ribosylation is another 
example of the biological diversifica-
tion that is characteristic of this gene 
family.
The best characterized human 
Sir2 homolog is SIRT1 (Blander and 
Guarente, 2004). SIRT1 is a nuclear 
protein that deacetylates substrates 
including histones, NF-κB, p53, 
FOXO proteins, PPARγ (peroxisome 
proliferator-activated receptor γ), the 
HIV Tat protein, and PGC-1α (PPARγ 
coactivator-1α). SIRT1 regulates cel-
lular processes as diverse as survival 
under stress, glucose homeosta-sis, and aging. Although SIRT6 and 
SIRT7 are also found in the nucleus, 
they do not colocalize with SIRT1 
(Michishita et al., 2005). In contrast 
to the euchromatic localization of 
SIRT1, SIRT6 associates with het-
erochromatin, whereas SIRT7 is 
concentrated in the nucleoli. In vitro 
studies have failed to demonstrate 
HDAC activity for SIRT6 and SIRT7; 
however, SIRT6 possesses robust 
auto-ADP-ribosyltransferase activity. 
Despite a possible role for SIRT6 in 
longevity (Mostoslavsky et al., 2006), 
the exact nature of the enzymatic 
activities and substrates of SIRT6 
and SIRT7 is unknown. SIRT2, found 
in both the nucleus and cytoplasm, 
deacetylates proteins such as α-
tubulin and regulates mitosis and the 
cell cycle. In sharp contrast to these 
sirtuins, SIRT3, SIRT4, and SIRT5 are 
found principally in the mitochon-
dria (Michishita et al., 2005). SIRT3 
possesses protein deacetylase 
activity and controls adaptive ther-
mogenesis; the function of SIRT5 is 
unknown.
SIRT4 is found in the mitochon-
dria of several cell types, including 
mouse pancreatic β cells. Despite 
having a conserved sirtuin domain, 
SIRT4 does not possess detectable 
deacetylase activity in vitro (Haigis 
et al., 2006). Instead, SIRT4 transfers 
an ADP-ribosyl group from NAD+ to 
histones, an activity that is sensitive 
to inhibition by nicotinamide (Haigis 
et al., 2006).. The mono-ADP-ribo-
syltransferase activity of SIRT4 is Cell 126, Sepnot a complete surprise because, 
although Sir2 is generally thought 
to be a NAD+-dependent protein 
deacetylase, it also possesses weak 
mono-ADP-ribosyltransferase activ-
ity (discussed by Smith and Denu, 
2006).
Posttranslational modification of 
protein substrates by mono-ADP-
ribosylation involves the creation 
of an N- or S-glycosidic linkage 
between a specific amino acid (such 
as arginine or cysteine) on the accep-
tor protein and the ADP-ribose resi-
due of NAD+. Several bacterial toxins 
exhibit mono-ADP-ribosylation activ-
ity; in mammalian cells, both intracel-
lular (endo-) and extracellular (ecto-) 
mono-ADP-ribosyltransferase reac-
tions exist. Several of the intracel-
lular reactions are associated with 
metabolism and cell signaling, with 
the β subunit of heterotrimeric G pro-
teins and GRP78/BiP, a chaperone 
resident in the endoplasmic reticu-
lum, as examples of substrates. The 
enzyme GDH was the first mitochon-
drial protein to be identified as being 
inactivated through mono-ADP-ribo-
sylation (Herrero-Yraola et al., 2001). 
Haigis et al. (2006) now identify 
SIRT4 as the enzyme responsible for 
the mono-ADP-ribosylation of GDH 
in vivo.
ADP-ribosylation of proteins can 
occur in one of two ways: nonenzy-
matic and enzymatic (Herrero-Yraola 
et al., 2001). In the nonenzymatic 
case, free ADP-ribose (a product 
of NAD+ glycohydrolase activity) is tember 8, 2006 ©2006 Elsevier Inc. 837
formed and then reacts nonenzy-
matically with nucleophilic amino 
acid residues to form covalent prod-
ucts. Many ADP-ribosyltransferases 
have inherent NAD+ glycohydrolase 
activity. In the case of enzymatic 
reactions, ADP-ribose is attached 
to proteins through the action of an 
ADP-ribosyltransferase. Given that 
SIRT4 does not seem to possess 
glycohydrolase activity, Haigis et al. 
surmised that SIRT4 may ADP-ribo-
sylate GDH through direct enzymatic 
transfer of ADP-ribose.
To demonstrate the consequence 
of this posttranslational modification 
by SIRT4, the authors tested GDH 
activity in wild-type mice and mice 
lacking SIRT4. Pancreatic cell mito-
chondrial lysates from SIRT4-defi-
cient animals exhibited increased 
GDH activity. Importantly, the GDH 
activity in the mitochondrial extracts 
from SIRT4-deficient mice, unlike 838 Cell 126, September 8, 2006 ©2006control mitochondrial extracts, was 
unaffected by phosphodiesterase, 
an enzyme known to cleave ADP-
ribose. This provided strong evi-
dence that GDH activity is inhibited 
by SIRT4-mediated ADP-ribosylation 
in vivo. Crucially, Haigis et al. (2006) 
next demonstrated that a key meta-
bolic consequence of SIRT4-medi-
ated ADP-ribosylation of GDH is the 
downregulation of insulin secretion in 
mouse pancreatic β cells in response 
to amino acids.
In the pancreatic β cell, mitochon-
dria serve to couple nutrient metab-
olism to the exocytosis of insulin, a 
process that can be stimulated by 
glucose or by amino acids (Maechler 
et al., 2006). Glucose-stimulated 
insulin secretion relies on the metab-
olism of glucose by glycolysis and 
the tricarboxylic acid cycle (TCA) to 
generate ATP. An increase in ATP 
closes ATP-sensitive K+ channels, Figure 1. Control of Amino Acid-Stimulated Insulin Secretion by Mitochondrial 
SIRT4 in the Pancreatic β Cell
Glucose is the most potent stimulator of insulin secretion. Glucose is taken up by the glucose 
transporters of pancreatic β cells and is metabolized via glycolysis and the TCA cycle, resulting 
in the formation of ATP. This results in the closure of ATP-dependent K+ channels, the opening 
of voltage-gated L-type Ca2+ channels, and promotion of insulin secretion by pancreatic β cells. 
Mitochondrial glutamate dehydrogenase (GDH) controls amino acid-stimulated insulin secretion 
by regulating glutamine and glutamate oxidative metabolism. Following exposure of the β cell 
to glutamine and depending on the energy state of the cell, the glutamate formed is converted 
by GDH to the TCA-cycle intermediate α-ketoglutarate. This promotes mitochondrial activation, 
ATP generation, and insulin secretion. GDH activity is under the tight control of allosteric effec-
tors—ADP and leucine activate GDH, whereas GTP inhibits it. GDH is also posttranslationally 
modified by mono-ADP-ribosylation mediated by SIRT4, which blocks GDH’s activity and thus 
prevents amino acid-stimulated insulin secretion. Elsevier Inc.which in turn depolarizes the plasma 
membrane, thus opening voltage-
gated L-type Ca2+ channels, hence 
facilitating insulin secretion (see 
Figure 1). The mechanism of amino 
acid-stimulated insulin secretion is 
less well characterized but is known 
to involve GDH activity. GDH cata-
lyzes the conversion of glutamate to 
the TCA-cycle intermediate α-keto-
glutarate. In this way, amino acids 
such as glutamine can be used as a 
fuel source to generate ATP and to 
stimulate insulin secretion (Figure 1). 
However, GDH is under strict alloste-
ric control, and glutamine (unlike glu-
cose) is not efficiently processed by 
oxidative metabolism under normal 
conditions. Glutamine oxidation can 
be promoted by allosteric activation 
of GDH by leucine, making leucine 
a potent insulin secretagogue. GDH 
sensitivity to leucine is regulated 
by the cellular GTP/ADP ratio; GDH 
activity is stimulated by ADP and L-
leucine but is blocked by GTP. Thus, 
under conditions favoring a low GTP/
ADP ratio, such as low glucose, GDH 
is sensitized to leucine and activated. 
Thus, leucine-induced GDH stimula-
tion of α-ketoglutarate formation 
is one mechanism by which amino 
acids stimulate insulin secretion. The 
importance of GDH in the control of 
pancreatic β cell function is under-
scored by mutations in the regulatory 
sites of human GDH, which render 
the enzyme insensitive to allosteric 
inhibition by GTP, resulting in hyper-
insulinemia and hyperammonemia.
SIRT4 may be a new face in the 
cast of modulators of GDH activity. 
In pancreatic β cells from SIRT4-
deficient mice, GDH is less ADP-
ribosylated and more active, leading 
to an increase in insulin secretion in 
response to amino acids. Another 
exciting observation is that, in SIRT4-
deficient animals, glutamine is nearly 
as effective as leucine in stimulating 
insulin secretion. This is reminiscent 
of pancreatic β cells with increased 
GDH activity (GDH overexpression 
or expression of dominant-active 
forms of GDH), which become more 
responsive to glutamine in terms of 
insulin secretion (Maechler et al., 
2006). How SIRT4 regulation of GDH 
ADP-ribosylation modulates the 
responsiveness of β cells to gluta-
mine remains unclear. Furthermore, 
given that glucose-stimulated insulin 
secretion is also increased in SIRT4-
deficient mice, this mouse model 
may help to sort out whether gluta-
mate and/or GDH act as an intracel-
lular messenger in this process.
In most tissues, GDH remains 
inactive (due to GTP inhibition) when 
cellular energy needs are sufficient 
(low ADP). However, when cellular 
energy demands increase, the ADP 
generated decreases the GTP inhi-
bition, thus permitting glutamate 
metabolism. In line with this rationale, 
under conditions of caloric restric-
tion, GDH was found to be less ADP-
ribosylated in pancreatic β cells, and 
insulin secretion was stimulated by 
amino acids. Therefore, Haigis et 
al. propose that caloric restriction 
downregulates SIRT4 activity and 
activates a switch to amino acid-
stimulated insulin secretion. This 
observation, however, goes against 
the expectation that sirtuin activity 
increases during caloric restriction, 
as is the case for yeast Sir2 (Blander 
and Guarente, 2004).
The evolutionary conservation of 
Sir2 and the sirtuins and their unusual 
dependence upon NAD+ consump-
tion to regulate a rapidly expand-
ing list of cellular processes—from 
gene silencing to the regulation of 
longevity—suggests that this class 
of enzymes may link transcriptional 
control with energy homeostasis 
(Blander and Guarente, 2004). Sir-
tuin-mediated control of metabolism 
occurs in a wide range of tissues 
and involves pleiotropic biological 
pathways. In white adipose tissue, 
SIRT1 decreases PPARγ activity and 
mobilizes free fatty acids (Picard et 
al., 2004). SIRT1 represses expres-
sion of UCP2 and increases glucose-
stimulated insulin secretion in pan-
creatic β cells (Bordone et al., 2006, 
Moynihan et al., 2005). In the liver, 
SIRT1 regulates gluconeogenesis 
through deacetylation and activation of the cofactor PGC-1α (Rodgers et 
al., 2005). Interestingly, PGC-1α is a 
master regulator of oxidative phos-
phorylation and energy homeostasis 
in mitochondria, the organelles that 
link energy metabolism and aging. 
So, it is not unexpected that mito-
chondrial sirtuins, such as SIRT3 
and SIRT4, would also be involved in 
mitochondrial energy homeostasis. In 
fact, SIRT3 modulates adaptive ther-
mogenesis in brown adipose tissue, 
a process confined to mitochondria. 
Through the regulation of acetyl-CoA 
synthetases, SIRT3 may also titrate 
mitochondrial fuel sources. The find-
ing that SIRT4 controls insulin secre-
tion in pancreatic β cells in response 
to amino acids fits with the notion 
that sirtuins control the mitochondrial 
energy supply. These observations, 
however, raise some evolutionary 
concerns about the sirtuin gene fam-
ily. Why has nature permitted evolu-
tion of the single Sir2 gene in yeast 
into a diverse family of paralogs in 
mammals (Michishita et al., 2005) 
with distinct enzymatic activities 
(deacetylation and ADP-ribosylation) 
that are connected to diverse physi-
ological pathways (DNA stability and 
metabolism) located in separate cel-
lular compartments (the nucleus and 
mitochondria)? Furthermore, differ-
ent sirtuins can have opposing activ-
ities on the same physiological path-
way, as exemplified by the negative 
and positive control of insulin secre-
tion by SIRT4 and SIRT1, respec-
tively. This diversification is all the 
more striking given that all of these 
activities are controlled by a single 
metabolite, NAD+.
From a mechanistic perspective, it 
remains unclear what completes the 
GDH/GDH-ADP-ribose cycle (Her-
rero-Yraola et al., 2001). For exam-
ple, is there an ADP-ribosylhydrolase 
yet to be identified, or is SIRT4 itself 
capable of reversing this posttrans-
lational modification? Furthermore, 
the authors do not completely rule 
out a substrate-specific deacetylase 
activity for SIRT4. The fact that many Cell 126, Septsirtuins remain orphaned in terms of 
their enzymatic activity, substrates, 
and regulatory functions suggests 
that we may be looking in the wrong 
places. Likewise, the physiologi-
cal relevance of SIRT4’s regulation 
of insulin secretion in the pancreas 
needs clarification. Does it play a role 
in adaptation during feeding or fast-
ing, for example? Could abnormali-
ties in ADP-ribosylation contribute to 
defects in pancreatic insulin secre-
tion that are characteristic of type 2 
diabetes? Further integrative studies 
should help to define the pleiotropic 
functions of the remarkable sirtuins 
and their role in aging, metabolic dis-
eases, and cancer.
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